• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.22% Nasdaq Up2.00%

    More On RVXCF

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials

    • Income Statement
    • Balance Sheet
    • Cash Flow

    Resverlogix Corp. (RVXCF)

    -Other OTC
    1.03 Down 0.06(5.50%) May 24, 11:13AM EDT
    ProfileGet Profile for:
    Resverlogix Corp.
    4820 Richard Road SW
    Suite 300
    Calgary, AB T3E 6L1
    Canada - Map
    Phone: 403-254-9252
    Fax: 403-256-8495
    Website: http://www.resverlogix.com

    Details 
    Index Membership:N/A
    Sector:N/A
    Industry:N/A
    Full Time Employees:22

    Business Summary 

    Resverlogix Corp., a clinical stage biotechnology company, develops small molecule therapeutics for Bromodomain and ExtraTerminal (BET) inhibition. The company is developing RVX-208, a small molecule selective BET domain inhibitor that is in clinical trials for the treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer’s disease, peripheral artery disease, and chronic kidney disease. Resverlogix Corp. is headquartered in Calgary, Canada.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Resverlogix Corp.

    Key Executives 
     PayExercised
    Mr. Donald J. McCaffrey ,
    Co-Founder, Chairman, Chief Exec. Officer, Pres and Sec.
    447.00K0.00
    Mr. Aaron Bradley Cann C.A., CBV,
    Chief Financial Officer
    273.00K0.00
    Mr. Kenneth Eugene Lebioda BA,
    Sr. VP of Bus. & Corp. Devel.
    228.00K0.00
    Dr. Jan O. Johansson M.D., Ph.D.,
    Sr. VP of Medical Affairs
    213.00K0.00
    Dr. Michael Sweeney M.D., 55
    Sr. VP of Clinical Devel.
    217.00K0.00
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.